Please Wait
Applying Filters...
menu
    • menu
    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.

    Virtual Booth

    Contact Supplier

    Transo-Pharm GmbH works globally to supply Active Pharmaceutical Ingredients adhering to the highest quality & GMP standards.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2025-01-20

    Virtual Booth

    Contact Supplier

    Menu

    Sunvozertinib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA Granted Priority Review to Dizal's Sunvozertinib NDA
    FDA Granted Priority Review to Dizal's Sunvozertinib NDA

    07 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/us-fda-granted-priority-review-to-dizals-sunvozertinib-new-drug-application-302344065.html

    PR NEWSWIRE
    07 Jan 2025
    Share Share
    Dizal Shows Sunvozertinib Data For EGFR-Resistant Lung Cancer
    Dizal Shows Sunvozertinib Data For EGFR-Resistant Lung Cancer

    11 Dec 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-announces-positive-pooled-data-of-sunvozertinib-in-egfr-tyrosine-kinase-inhibitor-resistant-non-small-cell-lung-cancer-published-in-lung-cancer-302328813.html

    PR NEWSWIRE
    11 Dec 2024
    Share Share
    Dizal Submits NDA for Sunvozertinib in EGFR Exon 20 NSCLC
    Dizal Submits NDA for Sunvozertinib in EGFR Exon 20 NSCLC

    08 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-submits-new-drug-application-to-the-us-fda-for-sunvozertinib-in-treating-relapsed-or-refractory-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302299834.html

    PR NEWSWIRE
    08 Nov 2024
    Share Share
    Sunvozertinib Shows Efficacy In NSCLC With EGFR Exon 20 Mutations
    Sunvozertinib Shows Efficacy In NSCLC With EGFR Exon 20 Mutations

    16 Sep 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/subgroup-analysis-from-pivotal-wu-kong1b-study-exhibits-robust-efficacy-of-sunvozertinib-in-non-small-cell-lung-cancer-patients-with-egfr-exon-20-insertion-mutations-across-different-baseline-characteristics-302250031.html

    PR NEWSWIRE
    16 Sep 2024
    Share Share
    Sunvozertinib's EGFR20Ins NSCLC Study Meets Primary Endpoint
    Sunvozertinib's EGFR20Ins NSCLC Study Meets Primary Endpoint

    02 Jun 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/sunvozertinibs-global-pivotal-wu-kong1b-study-meets-primary-endpoint-in-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302161228.html

    PR NEWSWIRE
    02 Jun 2024
    Share Share
    Dizal Sunvozertinib Egfr Exon 20: Biomarker Nsclc Mutation Treatment Analysis
    Dizal Sunvozertinib Egfr Exon 20: Biomarker Nsclc Mutation Treatment Analysis

    24 May 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/dizal-reveals-new-findings-from-biomarker-analysis-highlighting-sunvozertinib-as-an-effective-treatment-for-non-small-cell-lung-cancer-with-egfr-exon-20-insertion-mutations-302155056.html

    PR NEWSWIRE
    24 May 2024
    Share Share